Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Chapel Hill, North Carolina Clear all
Completed Phase 3 Interventional Results available

Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

NCT03268954
View directory record Official record
Conditions
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
Interventions
Azacitidine, Pevonedistat
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
128
States / cities
Daphne, Alabama • Mobile, Alabama • Goodyear, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 1 Interventional Results available

Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer

NCT04406623
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
Interventions
SL-172154
Drug
Lead sponsor
Shattuck Labs, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
Duarte, California • Grand Rapids, Michigan • Chapel Hill, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Terminated Not applicable Interventional Results available

Tailoring Maintenance Therapy to Cluster of Differentiation 5 Positive (CD5+) Regulatory B Cell Recovery in ANCA Vasculitis

NCT03906227
View directory record Official record
Conditions
ANCA Associated Vasculitis
Interventions
ENUMERATION OF CD5+ B Cells
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Jul 23, 2026, 11:48 AM EDT
Completed No phase listed Observational

Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery

NCT00033397
View directory record Official record
Conditions
Breast Cancer
Interventions
biopsy, magnetic resonance imaging, radiomammography, ultrasound imaging, gadopentetate dimeglumine, chemotherapy
Procedure · Radiation · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
5
States / cities
San Francisco, California • Chicago, Illinois • Minneapolis, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Jul 23, 2026, 11:48 AM EDT
Active, not recruiting Phase 3 Interventional

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Tiragolumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
34
States / cities
Hot Springs, Arkansas • Clovis, California • Duarte, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Tenofovir Rectal Douche to Prevent HIV Transmission Among Adolescents (ATN DREAM)

NCT04686279
View directory record Official record
Conditions
HIV/AIDS, HIV Prevention
Interventions
Tenofovir Douche
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
15 Years to 24 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia • Baltimore, Maryland • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Jul 23, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

Infant Formula in Infants and Children With Cow's Milk Allergy

NCT06456541
View directory record Official record
Conditions
Cow's Milk Allergy
Interventions
Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula
Other
Lead sponsor
Abbott Nutrition
Industry
Eligibility
3 Months to 12 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effect of Yogurt Containing BB12 on Children's Health and Child Care Absenteeism

NCT00653705
View directory record Official record
Conditions
Children's Health and Growth, Childcare Absenteeism
Interventions
Yogurt drink with probiotic bacteria BB12, Placebo
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Months to 48 Months
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging

NCT04021238
View directory record Official record
Conditions
Kidney Cancer
Interventions
Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years to 99 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Jul 23, 2026, 11:48 AM EDT
Recruiting Not applicable Interventional

Integrating Biological, Clinical, and Behavioral Factors to Improve Breast Cancer Outcomes - Carolina Breast Cancer Study

NCT07214610
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
Structured behavioral intervention
Behavioral
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
20 Years to 74 Years · Female only
Enrollment
3,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2044
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Recruiting No phase listed Observational

Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT04099290
View directory record Official record
Conditions
Head and Neck Neoplasm, Carcinoma, Squamous Cell
Interventions
Blood and tumor samples
Other
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study: Focused Ultrasound Thalamotomy for the Prevention of Secondary Generalization in Focal Onset Epilepsy

NCT03417297
View directory record Official record
Conditions
Partial Seizures With Secondary Generalization, Focal Epilepsy With Secondary Generalization
Interventions
High Intensity Focused Ultrasound
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Recruiting Phase 2 Interventional

The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study

NCT05538208
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Mycophenolate Mofetil
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
8 Years to 20 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
19
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Not listed Phase 3 Interventional

A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Breast Cancer

NCT00486668
View directory record Official record
Conditions
Invasive Breast Cancer
Interventions
doxorubicin, cyclophosphamide, paclitaxel, trastuzumab, lapatinib
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
103
States / cities
Mobile, Alabama • La Jolla, California • Long Beach, California + 88 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2016 · Synced Jul 23, 2026, 11:48 AM EDT
Not yet recruiting Not applicable Interventional

Feasibility, Acceptability, and Safety Trial of Brief, Breath Control-Focused Acceptance and Commitment Therapy in Adults With Chronic Cough

NCT07566117
View directory record Official record
Conditions
Chronic Cough
Interventions
Acceptance and Commitment Therapy (ACT)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Results available

Immune Modulators for Treating COVID-19

NCT04593940
View directory record Official record
Conditions
Covid19
Interventions
Infliximab, Abatacept, Remdesivir, cenicriviroc (closed to enrollment as of 3-Sep-2021)
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
18 Years and older
Enrollment
1,971 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
67
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 54 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2023 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis

NCT05064735
View directory record Official record
Conditions
Obesity
Interventions
semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Not listed
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
61
States / cities
Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2025 · Synced Jul 23, 2026, 11:48 AM EDT
Terminated Early Phase 1 Interventional

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lung Clearance Index, MRI with PFP
Device · Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Jul 23, 2026, 11:48 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Keep Social Study for Young Adults

NCT07005817
View directory record Official record
Conditions
Social Isolation, Loneliness
Interventions
Experimental Health Communication, Simulated Social Media Platform Only
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 29 Years
Enrollment
1,900 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Recruiting No phase listed Observational

Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring

NCT05974150
View directory record Official record
Conditions
Breast Cancer, Lung Cancer, Multiple Myeloma, Ovarian Cancer, Acute Myelogenous Leukemia
Interventions
Web based survey
Other
Lead sponsor
Carevive Systems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Evanston, Illinois • Chapel Hill, North Carolina + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 2 Interventional Results available

MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery

NCT01425879
View directory record Official record
Conditions
Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma, Recurrent Adult Liver Carcinoma, Recurrent Gallbladder Carcinoma, Stage IV Distal Bile Duct Cancer, Stage IV Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Carcinoma, Unresectable Gallbladder Carcinoma
Interventions
Akt Inhibitor MK2206, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2016 · Synced Jul 23, 2026, 11:48 AM EDT
Completed Phase 1Phase 2 Interventional

Safety Study of Inhaled 552-02 in Cystic Fibrosis Patients

NCT00274313
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
552-02
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
14 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
15
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2009 · Synced Jul 23, 2026, 11:48 AM EDT
Active, not recruiting No phase listed Observational

Ascertaining Longterm Outcomes of Fibroid Treatments

NCT06430320
View directory record Official record
Conditions
Uterine Fibroid
Interventions
NA- no intervention
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
San Francisco, California • Detroit, Michigan • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 23, 2026, 11:48 AM EDT